Cargando…

Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer

SIMPLE SUMMARY: α6β4-integrins and plectin are the key structural components of hemidesmosomes that have been implicated in carcinogenesis and which are thus considered as potential cancer biomarkers and drug targets for anti-cancer therapies. In this review, we elaborate on the current knowledge of...

Descripción completa

Detalles Bibliográficos
Autores principales: Koivusalo, Saara, Schmidt, Anette, Manninen, Aki, Wenta, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818203/
https://www.ncbi.nlm.nih.gov/pubmed/36612146
http://dx.doi.org/10.3390/cancers15010149
_version_ 1784864927584878592
author Koivusalo, Saara
Schmidt, Anette
Manninen, Aki
Wenta, Tomasz
author_facet Koivusalo, Saara
Schmidt, Anette
Manninen, Aki
Wenta, Tomasz
author_sort Koivusalo, Saara
collection PubMed
description SIMPLE SUMMARY: α6β4-integrins and plectin are the key structural components of hemidesmosomes that have been implicated in carcinogenesis and which are thus considered as potential cancer biomarkers and drug targets for anti-cancer therapies. In this review, we elaborate on the current knowledge of the kinase signaling pathways regulated by α6β4-integrins and plectin in the context of prostate cancer. We discuss an emerging scenario where hemidesmosomal α6β4-integrins and plectin function as tumor suppressors but adopt new oncogenic roles upon hemidesmosome disassembly in prostate cancer. ABSTRACT: Hemidesmosomes (HDs) are adhesive structures that ensure stable anchorage of cells to the basement membrane. They are formed by α6β4-integrin heterodimers and linked to intermediate filaments via plectin. It has been reported that one of the most common events during the pathogenesis of prostate cancer (PCa) is the loss of HD organization. While the expression levels of β4-integrins are strongly reduced, the expression levels of α6-integrins and plectin are maintained or even elevated, and seem to promote tumorigenic properties of PCa cells, such as proliferation, invasion, metastasis, apoptosis- and drug-resistance. In this review, we discuss the potential mechanisms of how HD components might contribute to various cellular signaling pathways to promote prostate carcinogenesis. Moreover, we summarize the current knowledge on the involvement of α6β4-integrins and plectin in PCa initiation and progression.
format Online
Article
Text
id pubmed-9818203
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98182032023-01-07 Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer Koivusalo, Saara Schmidt, Anette Manninen, Aki Wenta, Tomasz Cancers (Basel) Review SIMPLE SUMMARY: α6β4-integrins and plectin are the key structural components of hemidesmosomes that have been implicated in carcinogenesis and which are thus considered as potential cancer biomarkers and drug targets for anti-cancer therapies. In this review, we elaborate on the current knowledge of the kinase signaling pathways regulated by α6β4-integrins and plectin in the context of prostate cancer. We discuss an emerging scenario where hemidesmosomal α6β4-integrins and plectin function as tumor suppressors but adopt new oncogenic roles upon hemidesmosome disassembly in prostate cancer. ABSTRACT: Hemidesmosomes (HDs) are adhesive structures that ensure stable anchorage of cells to the basement membrane. They are formed by α6β4-integrin heterodimers and linked to intermediate filaments via plectin. It has been reported that one of the most common events during the pathogenesis of prostate cancer (PCa) is the loss of HD organization. While the expression levels of β4-integrins are strongly reduced, the expression levels of α6-integrins and plectin are maintained or even elevated, and seem to promote tumorigenic properties of PCa cells, such as proliferation, invasion, metastasis, apoptosis- and drug-resistance. In this review, we discuss the potential mechanisms of how HD components might contribute to various cellular signaling pathways to promote prostate carcinogenesis. Moreover, we summarize the current knowledge on the involvement of α6β4-integrins and plectin in PCa initiation and progression. MDPI 2022-12-27 /pmc/articles/PMC9818203/ /pubmed/36612146 http://dx.doi.org/10.3390/cancers15010149 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Koivusalo, Saara
Schmidt, Anette
Manninen, Aki
Wenta, Tomasz
Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer
title Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer
title_full Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer
title_fullStr Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer
title_full_unstemmed Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer
title_short Regulation of Kinase Signaling Pathways by α6β4-Integrins and Plectin in Prostate Cancer
title_sort regulation of kinase signaling pathways by α6β4-integrins and plectin in prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818203/
https://www.ncbi.nlm.nih.gov/pubmed/36612146
http://dx.doi.org/10.3390/cancers15010149
work_keys_str_mv AT koivusalosaara regulationofkinasesignalingpathwaysbya6b4integrinsandplectininprostatecancer
AT schmidtanette regulationofkinasesignalingpathwaysbya6b4integrinsandplectininprostatecancer
AT manninenaki regulationofkinasesignalingpathwaysbya6b4integrinsandplectininprostatecancer
AT wentatomasz regulationofkinasesignalingpathwaysbya6b4integrinsandplectininprostatecancer